Concord Biotech is currently trading at Rs. 1330.50, up by 58.95 points or 4.64% from its previous closing of Rs. 1271.55 on the BSE.
The scrip opened at Rs. 1288.90 and has touched a high and low of Rs. 1346.20 and Rs. 1285.05 respectively. So far 50234 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2149.90 on 11-Jun-2025 and a 52 week low of Rs. 987.05 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1,346.20 and Rs. 1,023.05 respectively. The current market cap of the company is Rs. 14018.57 crore.
The promoters holding in the company stood at 44.08%, while Institutions and Non-Institutions held 17.02% and 38.90% respectively.
Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA).
The approval positions the company to capitalize on attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
